Investigational Drug Shows Potentialin Phase 3 Obesity Trial - Top-Institutions - MDSpire

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.

  • By

  • Andrea Surnit

  • June 10, 2026

  • 4 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    University College Dublin School of Medicine
    University College Dublin School of Medicine

    Dublin, Ireland

    Key Differentiators

    • Endocrinology

  • #2

    National Institute of Diabetes and Digestive and Kidney Diseases
    National Institute of Diabetes and Digestive and Kidney Diseases

    Bethesda, Maryland

    Key Differentiators

    • Endocrinology

  • #3

    Clalit Health Services
    Clalit Health Services

    Tel Aviv, Israel

    Key Differentiators

    • Endocrinology

  • #4

    Hasharon Hospital at the Rabin Medical Center
    Hasharon Hospital at the Rabin Medical Center

    Petah Tikva, Israel

    Key Differentiators

    • Endocrinology

  • #5

    University of Copenhagen
    University of Copenhagen

    Copenhagen, Denmark

    Key Differentiators

    • Endocrinology

Original Source(s)

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

  • by Andrea Surnit

  • June 10, 2026

Related Content

Study Reassures on Safety of Early NSAID Use

A large cohort found no adjusted link to major congenital malformations, but questions remain for miscarriage, later pregnancy, and other outcomes.

Nationwide prospective cohort study in China: the impact of cumulative modified cardiometabolic index on cardiovascular disease incidence

Molecular Interplay between hypertension and dyslipidemia in cardiovascular pathogenesis: toward precision-based therapeutic strategies